Live Events
Here is a look at the weightloss drugs prices in India:
Drugmaker Dosage Type Weekly Price (₹) Monthly Price (₹) Notes on Novo/Lilly Sales in India Natco Pharma Injection - 1,290 Generic launch post-patent expiry Alkem Labs Injection 450 1,800 - Sun Pharma Injection 750–900 - - Dr. Reddy’s Injection - 4,200 - Lupin / Zydus Injection - 2,200 - Torrent Pharmaceuticals Oral & Injection - 3,999 - Lilly Mounjaro Injection - 13,125–25,781 Original brand prices Novo Wegovy Injection - 10,850 Price cut in Nov; Ozempic Rs 8,800 monthly
as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!
(You can now subscribe to our
(You can now subscribe to our Economic Times WhatsApp channel
With the patent expiry of Lilly and Novo’s weight-loss drugs in India on March 20, at least six generic drugmakers have already launched their versions, intensifying competition in the country’s obesity treatment market.Lilly’squickly gained traction in India, last year. A 2.5 mg Mounjaro KwikPen costs about Rs 13,125 for a month’s usage, with the highest 15 mg dose going up to RS 25,781.Novo cut the price ofin India by up to 37% in November, pricing its lowest dose of 0.25 mg at Rs 10,850 for a one-month pack. It also launchedsoon after for Rs 8,800 per month for the 0.25 mg dose.India’s obesity drug market could grow to Rs 8,000 crore by 2030 from about Rs 1,500 crore today, according to Pharmarack estimates.More than 40 Indian firms are expected to launch over 50 brands within weeks, analysts and doctors said, widening access in a price-sensitive market, Reuters reported earlier this week, adding that experts caution this could also lead to misuse and confusion among prescribers as costs fall sharply, Reuters reported earlier this week.India, the world’s most populous nation, has the second-highest number of adults with diabetes after China and could have more than 440 million overweight or obese people by 2050, according to The Lancet and the International Diabetes Federation.